Cargando…
Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies
In recent years, the excellent curative effect of CD19‐specific chimeric antigen receptor (CAR) T‐cell therapy has brought hope to patients with relapsing or refractory B‐cell hematological malignancies, however relapse after CAR T‐cell infusion has hindered the widespread clinical application of th...
Autores principales: | Guo, Zhenling, Tu, Sanfang, Yu, Siyao, Wu, Liufang, Pan, Wanying, Chang, Ning, Zhou, Xuan, Song, Chaoyang, Li, Yuhua, He, Yanjie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019219/ https://www.ncbi.nlm.nih.gov/pubmed/33416209 http://dx.doi.org/10.1111/cas.14799 |
Ejemplares similares
-
CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
por: Tu, Sanfang, et al.
Publicado: (2019) -
Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies
por: Xiao, Xinyi, et al.
Publicado: (2022) -
Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
por: Zhou, Xuan, et al.
Publicado: (2020) -
Chimeric antigen T cell receptor treatment in hematological malignancies
por: Ali, Natasha
Publicado: (2019) -
Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies
por: Yan, Weiqi, et al.
Publicado: (2020)